REBACIN® as a noninvasive clinical intervention for high-risk human papillomavirus persistent infection.
Yang Y, Meng YL, Duan SM, Zhan SB, Guan RL, Yue TF, Kong LH, Zhou L, Deng LH, Huang C, Wang S, Wang GY, Wu DF, Zhang CF, Chen F.
Yang Y, et al.
Int J Cancer. 2019 Nov 15;145(10):2712-2719. doi: 10.1002/ijc.32344. Epub 2019 Apr 29.
Int J Cancer. 2019.
PMID: 30989655
Free article.
Clinical Trial.